QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 omega-therapeutics-restructuring-committee-approved-workforce-reduction-of-up-to-17-employees-for-cost-reduction-amid-chapter-11-case-and-potential-asset-sale

https://www.sec.gov/ix?doc=/Archives/edgar/data/1850838/000119312525019359/d927659d8k.htm On February 3, 2025, the Company, wit...

 omega-therapeutics-receives-default-notice-from-banc-of-california-disputes-alleged-breach-of-loan-terms-bank-sets-off-1467m-deposits-maintains-compliance-claims-seeks-resolution

On January 13, 2025, Omega Therapeutics, Inc. (the "Company") received a notice of default (the "Notice of Default&...

 omega-therapeutics-receives-non-binding-proposal-from-mirai-bio-to-modify-terms-of-research-collaboration-agreement-with-novo-nordisk-and-pioneering-medicines-08---filing

Under the terms of the Proposal, Mirai would acquire all of the Company's rights and obligations under the Collaboration Ag...

 piper-sandler-maintains-overweight-on-omega-therapeutics-lowers-price-target-to-4

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:OMGA) with a Overweight and lowers the price targ...

 omega-therapeutics-q3-2024-gaap-eps-030-misses-028-estimate-sales-2612m-beat-1240m-estimate

Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of ...

 omega-therapeutics-completes-phase-1-mychelangelo-i-clinical-trial-and-a-strategic-prioritization-of-its-pipeline

Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from compl...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION